Skip to main content

Advertisement

SpringerLink
Log in

Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

  • Special Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The study analyzes the current status of personalized medicine in pediatric oncology in Spain. It gathers national data on the tumor molecular studies and genomic sequencing carried out at diagnosis and at relapse, the centers that perform these studies, the technology used and the interpretation and clinical applicability of the results. Current challenges and future directions to achieve a coordinated national personalized medicine strategy in pediatric oncology are also discussed. Next generation sequencing-based (NGS) gene panels are the technology used in the majority of centers and financial limitations are the main reason for not incorporating these studies into routine care. Nowadays, the application of precision medicine in pediatric oncology is a reality in a great number of Spanish centers. However, its implementation is uneven and lacks standardization of protocols; therefore, national coordination to overcome the inequalities is required. Collaborative work within the Personalized Medicine Group of SEHOP is an adequate framework for encouraging a step forward in the effort to move precision medicine into the national healthcare system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

All information derived from the study is included in the paper itself, as well as in the supplementary material.

Code availability

Not applicable.

References

  1. Sweet-Cordero EA, Biegel JA. The genomic landscape of pediatric cancers: implications for diagnosis and treatment. Science. 2019;363(6432):1170–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Forrest SJ, Geoerger B, Janeway KA. Precision medicine in pediatric oncology. Curr Opin Pediatr. 2018;30(1):17–24.

    Article  PubMed  Google Scholar 

  3. Jones DTW, Banito A, Grünewald TGP, Haber M, Jäger N, Kool M, et al. Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. Nat Rev Cancer. 2019;19(8):420–38.

    Article  CAS  PubMed  Google Scholar 

  4. Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA. 2015;314(9):913–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, et al. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the individualized cancer therapy (iCat) study. JAMA Oncol. 2016;2(5):608–15.

    Article  PubMed  Google Scholar 

  6. Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016;2(5):616–24.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, et al. Next-generation personalised medicine for high-risk paediatric cancer patients—the INFORM pilot study. Eur J Cancer. 2016;65:91–101.

    Article  PubMed  Google Scholar 

  8. Pincez T, Clément N, Lapouble E, Pierron G, Kamal M, Bieche I, et al. Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. Pediatr Blood Cancer. 2017;64:6.

    Article  Google Scholar 

  9. Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, et al. Implementation of next generation sequencing into pediatric hematology–oncology practice: moving beyond actionable alterations. Genome Med. 2016;8(1):133.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, Auger N, et al. Molecular Screening for cancer treatment optimization (MOSCATO-01) in pediatric patients: a single-institutional prospective molecular stratification trial. Clin Cancer Res. 2017;23(20):6101–12.

    Article  CAS  PubMed  Google Scholar 

  11. Evans WE, Pui CH, Yang JJ. The promise and the reality of genomics to guide precision medicine in pediatric oncology: the decade ahead. Clin Pharmacol Ther. 2020;107(1):176–80.

    Article  CAS  PubMed  Google Scholar 

  12. Le Tourneau C, Kamal M, Tsimberidou AM, Bedard P, Pierron G, Callens C, et al. Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials. J Natl Cancer Inst. 2015;108(4):djv362.

    Article  PubMed Central  Google Scholar 

  13. Mody RJ, Prensner JR, Everett J, Parsons DW, Chinnaiyan AM. Precision medicine in pediatric oncology: lessons learned and next steps. Pediatr Blood Cancer. 2017;64:3. https://doi.org/10.1002/pbc.26288.

    Article  Google Scholar 

  14. Pardo E, Muñoz A, Valero S, Porta S, Cañete A, Barreda MS, et al. Cáncer infantil en España. Estadísticas 1980–2019. Registro Español de Tumores Infantiles (RETI-SEHOP). 2020. https://www.uv.es/rnti/pdfs/Informe_RETI-SEHOP_1980-2017.pdf. Accessed 26 Aug 2021.

  15. Allen CE, Laetsch TW, Mody R, Irwin MS, Lim MS, Adamson PC, et al. Target and agent prioritization for the children’s oncology group-national cancer institute pediatric MATCH trial. J Natl Cancer Inst. 2017;109(5):djw274.

    Article  PubMed Central  Google Scholar 

  16. Wong M, Mayoh C, Lau LMS, Khuong-Quang DA, Pinese M, Kumar A, et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020;26(11):1742–53.

    Article  CAS  PubMed  Google Scholar 

  17. Grünewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Álava E, Kovar H, et al. Ewing sarcoma. Nat Rev Dis Primers. 2018;4(1):5.

    Article  PubMed  Google Scholar 

  18. Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014;4(11):1326–41.

    Article  CAS  PubMed  Google Scholar 

  19. Surrey LF, MacFarland SP, Chang F, Cao K, Rathi KS, Akgumus GT, et al. Clinical utility of custom-designed NGS panel testing in pediatric tumors. Genome Med. 2019;11(1):32.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Jørgensen JT. Site-agnostic biomarker-guided oncology drug development. Expert Rev Mol Diagn. 2020;20(6):583–92.

    Article  PubMed  Google Scholar 

  21. Moorcraft SY, Gonzalez D, Walker BA. Understanding next generation sequencing in oncology: a guide for oncologists. Crit Rev Oncol Hematol. 2015;96(3):463–74.

    Article  PubMed  Google Scholar 

  22. Hinrichs JW, van Blokland WT, Moons MJ, Radersma RD, Radersma-van Loon JH, de Voijs CM, et al. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice. Am J Clin Pathol. 2015;143(4):573–8.

    Article  PubMed  Google Scholar 

  23. de Rojas T, Kasper B, Van der Graaf W, Pfister SM, Bielle F, Ribalta T, et al. EORTC SPECTA-AYA: a unique molecular profiling platform for adolescents and young adults with cancer in Europe. Int J Cancer. 2020;147(4):1180–4.

    Article  PubMed  Google Scholar 

  24. Ripperger T, Bielack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, et al. Childhood cancer predisposition syndromes—a concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet A. 2017;173(4):1017–37.

    Article  PubMed  Google Scholar 

  25. Brodeur GM, Nichols KE, Plon SE, Schiffman JD, Malkin D. Pediatric Cancer predisposition and surveillance: an overview, and a tribute to Alfred G. Knudson. Jr Clin Cancer Res. 2017;23(11):e1–5.

    Article  PubMed  Google Scholar 

  26. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Scollon S, Anglin AK, Thomas M, Turner JT, Wolfe SK. A comprehensive review of pediatric tumors and associated cancer predisposition syndromes. J Genet Couns. 2017;26(3):387–434.

    Article  PubMed  Google Scholar 

  28. Jongmans MC, Loeffen JL, Waanders E, Hoogerbrugge PM, Ligtenberg MJ, Kuiper RP, et al. Recognition of genetic predisposition in pediatric cancer patients: an easy-to-use selection tool. Eur J Med Genet. 2016;59(3):116–25.

    Article  PubMed  Google Scholar 

  29. Ahmed AA, Vundamati DS, Farooqi MS, Guest E. Precision medicine in pediatric cancer: current applications and future prospects. High Throughput. 2018;7(4):39.

    Article  CAS  PubMed Central  Google Scholar 

  30. DuBois SG, Corson LB, Stegmaier K, Janeway KA. Ushering in the next generation of precision trials for pediatric cancer. Science. 2019;363(6432):1175–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

To SEHOP (Spanish Society of Pediatric Hematogy and Oncology) for its support in the execution of this study and the performance of the group's tasks. We are grateful to the president of the society, Dr. Ana Fernández-Teijeiro, for the support given for the creation of the Personalized Medicine working group. The authors thank Radek Sucháč for his work with English editing.

Funding

SEHOP has received financial support for this project in the form of unrestricted collaboration in the logistics of expert meeting from Bayer.

Author information

Authors and Affiliations

  1. Research Institute Hospital La Fe, Valencia, Spain

    P. Gargallo

  2. Oncology Department, Health in Code Group, Paterna, Valencia, Spain

    P. Gargallo & I. Calabria

  3. Clinical Trials Unit, Pediatric Hematology-Oncology Division, Hospital Universitario Niño Jesús, Madrid, Spain

    F. Bautista & A. Rubio-San-Simón

  4. Pediatric Oncology and Hematology Unit, La Fe University Hospital, Valencia, Spain

    A. Juan-Ribelles & A. Cañete

  5. Pediatric OncoGenomics Unit, Pediatric Hematology-Oncology Department, Children’s University Hospital Niño Jesús, Madrid, Spain

    E. Izquierdo & T. de Rojas

  6. Group of Translational Research in Child and Adolescent Cancer, Vall d’Hebron Research Institute (VHIR)-Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

    A. Soriano, R. Hladun & L. Moreno

  7. Translational Research in Pediatric Oncology, Hematopoietic Stem Cell Transplantation, Cell Therapy, INGEMM-IdiPAZ, La Paz University Hospital, Madrid, Spain

    A. Escudero

  8. Laboratory of Molecular Oncology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain

    C. Lavarino & N. G. Olaciregui

  9. Department of Pediatric Oncology, Hospital Infantil Virgen del Rocio, Sevilla, Spain

    P. Solano

  10. Vall d’Hebron University Hospital, Barcelona, Spain

    R. Hladun & L. Moreno

  11. Pediatric Hematology and Oncology Unit, Madrid Montepríncipe Hospital, Madrid, Spain

    I. Martínez-Romera

  12. Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Spain

    A. Castañeda-Heredia

  13. Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Sevilla/CIBERONC, Sevilla, Spain

    E. de Álava

  14. Pediatric Hemato-Oncology Department, Hospital Universitario La Paz, Madrid, Spain

    A. Pérez-Martínez

  15. Servicio de Pediatria, Bio Cruces Health Research Institute, Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain

    I. Astigarraga

  16. Departamento de Pediatria, Universidad del Pais Vasco UPV/EHU, Leioa, Spain

    I. Astigarraga

  17. Laboratory and Department of Pediatrics, University Clinic of Navarra and Solid Tumor Area, CIMA, IdiSNA, Pamplona, Spain

    A. Patiño-García

  18. Instituto de Investigación de Enfermedades Raras and U758 (CB06/07/1009), CIBERER, Instituto de Salud Carlos III, Unidad de Tumores Sólidos Infantiles, Madrid, Spain

    J. Alonso

  19. Pediatric Oncology and Hematology Unit, Hospital Universitario Virgen Macarena, Seville University, Seville, Spain

    A. Fernández-Teijeiro

Authors
  1. P. Gargallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Bautista
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Juan-Ribelles
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Izquierdo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Soriano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. de Rojas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Escudero
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Lavarino
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Solano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. Hladun
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Rubio-San-Simón
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. I. Martínez-Romera
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. I. Calabria
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. N. G. Olaciregui
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A. Castañeda-Heredia
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. E. de Álava
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. A. Pérez-Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. I. Astigarraga
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. A. Patiño-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. J. Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. A. Fernández-Teijeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. A. Cañete
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. L. Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by LM, AJ-R, and PG. The first draft of the manuscript was written by PG and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript after making significant changes to the text.

Corresponding author

Correspondence to P. Gargallo.

Ethics declarations

Competing interests

LM is a member of data monitoring committees for clinical trials sponsored by Novartis, Actuate Therapeutics, Shionogi, Incyte, the University of Southampton and the Royal Marsden NHS Foundation Trust; and has had a consulting role for Novartis and Shionogi. LM is also member of the Executive Committee of SIOPEN (European neuroblastoma research cooperative group), an organization which receives royalties for the sales of dinutuximab beta. The remaining authors declare no conflict of interest.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Ethical standards

The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The manuscript does not contain clinical studies or patient data.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 17 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gargallo, P., Bautista, F., Juan-Ribelles, A. et al. Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clin Transl Oncol 24, 809–815 (2022). https://doi.org/10.1007/s12094-021-02759-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-021-02759-7

Keywords

Search

Navigation